Stock TNGX TANGO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Market Closed - Nasdaq
Other stock markets
 01:30:00 18/06/2024 am IST 		5-day change 1st Jan Change
9.38 USD +5.04% Intraday chart for Tango Therapeutics, Inc. +31.01% -5.25%
11/06 Transcript : Tango Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM
28/05 HC Wainwright Adjusts Price Target on Tango Therapeutics to $13 From $17, Maintains Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Tango Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM
Tango Therapeutics : Corporate Presentation
PU
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BU
HC Wainwright Adjusts Price Target on Tango Therapeutics to $13 From $17, Maintains Buy Rating
MT
Guggenheim Adjusts Tango Therapeutics Price Target to $14 From $16, Maintains Buy Rating
MT
Barclays Adjusts Tango Therapeutics Price Target to $13 From $18, Maintains Overweight Rating
MT
Wedbush Adjusts Tango Therapeutics Price Target to $11 From $18, Maintains Outperform Rating
MT
Tango Therapeutics Stops Development of USP1 Inhibitor After Liver Toxicity Issues
MT
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
MT
Sector Update: Health Care
MT
Tango Therapeutics Discontinues TNG348 Program After Showing Liver Toxicity in Trials; Shares Tumble Premarket
MT
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
PR
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
AQ
Tango Therapeutics to stop development of cancer therapy
RE
Tango Therapeutics : Corporate Presentation
PU
Tango Therapeutics Announces Discontinuation of TNG348 Program
BU
Tango Therapeutics Announces Discontinuation of TNG348 Program
CI
Tango Appoints Tim Redfern as Chief Financial Officer
CI
Tango Therapeutics : Corporate Presentation
PU
Tango Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TNGX Stock
  4. News Tango Therapeutics, Inc.